Attention Turns To Celgene's Other Pipeline Prospects Following Second Positive Luspatercept Read-Out

Celgene and Acceleron's novel erythroid maturation agent, luspatercept, has reported positive Phase III results in a second potential indication, beta-thalassemia, and approval filings are confirmed for the first half of 2019.